Centers for Disease Control and Prevention (CDC), Procurement & Grants Office, 255 East Paces Ferry Road, N.E., Room No. 405 Atlanta, Georgia 30305

A -- A COMPARISON OF SPECIFICITY OF COMMERCIALLY AVAILABLE TUBERCULIN SKIN TEST ANTIGENS FOR DETECTING INFECTION WITH MYCOBACTERIUM TUBERCULOSIS SOL 200-96-0505(P) DUE 070296 POC Contact Elmira C. Benson, Contract Specialist at (404)842-6790 The Centers for Disease Control and Prevention (CDC) contemplates the award of a cost plus fixed-fee contract to conduct a clinical trial. The objective of the trial is to determine if the two tuberculin skin test antigens which are commercially available (Aplisol and Tubersol) in the United States produce a similar distribution of reactivity in populations at very low risk for infections with M. tuberculosis. To be eligible for award each offeror must meet the following ABSOLUTE CRITERIA FOR ELIGIBILITY: Demonstrate the ability to identify and recruit into a skin testing clinical trial, a minimum of 250 subjects asymptomatic of TB who, because of their history, are very unlikely to be infected with HIV or M. tuberculosis (i.e., they have no history of BCG vaccination and they are a member of a population where the induration size for defining a positive tuberculin skin test would be greater than or equal to 15 mm). The contemplated period of performance is 12 months. More than one award is contemplated as a result of this solicitation. Requests for solicitation must cite RFP 200-96-0505(P). The RFP due date is approximately 45 days aftersolicitation release date which will be on or about May 15, 1996. NO TELEPHONE REQUESTS FOR COPIES OF THE RFP WILL BE ACCEPTED. However, requests transmitted via facsimile are acceptable. The facsimile number is (404) 842-6896. All responsible sources may submit a proposal which shall be considered by the Agency. (0110)

Loren Data Corp. http://www.ld.com (SYN# 0010 19960422\A-0010.SOL)